Abstract
Atopic eczema is a pruritic chronic skin condition. The initial manifestations can occur at any age; however, in general, they occur in two thirds of patients by two years of age.
The aetiopathogenesis of atopic eczema is multifactorial with local cutaneous, neurohumoral, and immunological abnormalities. The consumption of corticosteroids still remains high.
Immunomodulators are drugs that reduce the consumption of hormonal products. Elidel is among the first-choice drugs when the condition occurs on sensitive sites of the skin.
According to the 5-year Petite study 2004–2010, in which infants aged 3 to 12 months were included at study baseline, no negative effect was shown on the development of the immune system or the growth rate.